🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Intranasal insulin ameliorates prenatal LPS-induced learning and memory impairments in adolescent male rats: A behavioral, electrophysiological, and molecular study.

PMID: 41723234 · DOI: 10.1038/s41598-026-40163-9 · Scientific reports, 2026 · Hadis Kariminejad-Farsangi, Haniyeh Kariminejad-Farsangi, Mohammad Amin Rajizadeh, Mahdiyeh Abbaspoor, Lily Mohammadipoo
📄 Abstract

Prenatal stress, including maternal immune activation (MIA), affects cognitive performance in the offspring. Since insulin could improve cognitive function in several aspects, we hypothesized that intranasal insulin would attenuate MIA-induced learning and memory deficits. In the present study, the pregnant Wistar rats received lipopolysaccharide (LPS, 250 µg/kg) intraperitoneally on gestational day 15. Intranasal insulin (2 IU, 7 days) was administered to male pups from PND 34-47. During late adolescence, the Morris Water Maze and in vivo electrophysiological recording were performed in male rats to assess spatial learning and memory and long-term potentiation (LTP), respectively. Also, the hippocampal expression of BDNF and PSD-95 was evaluated using real-time PCR. Our results demonstrated that MIA impaired spatial learning and memory in the male pups. Hippocampal synaptic plasticity was also impaired in the adolescent male rats. However, intranasal administration of insulin could overcome MIA-induced impairments and improve learning, memory, and synaptic plasticity in the male pups. Although BDNF and PSD-95 levels were not altered in the hippocampus of MIA pups, intranasal insulin increased PSD-95 expression. Taken together, these findings suggest that intranasal insulin promotes cognitive performance in MIA-exposed pups during adolescence; however, the underlying molecular mechanisms remain to be elucidated.

Confidence: 0.26 · 14 полей извлечено
Идентификация (6 полей)
Target
insulin
0.90
Alt. target
0.00
Protein family
insulin family
0.80
Functional class
hormone
0.80
Subcellular loc.
secreted
0.70
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
0.00
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
hippocampal expression of BDNF and PSD-95
0.90
In vitro
0.00
In vivo
Intranasal insulin (2 IU, 7 days) administered to male pups from PND 34-47; Morris Water Maze and in vivo electrophysiological recording performed in male rats; hippocampal expression of BDNF and PSD-95 evaluated using real-time PCR
0.95
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
pregnant Wistar rats; male pups
0.95
Diet/model
prenatal LPS (250 µg/kg) intraperitoneally on gestational day 15
0.95
Клиника (11 полей)
Drug
Insulin
0.95
Indication
Cognitive impairment associated with maternal immune activation (MIA)
0.80
Patient subgroups
Adolescent males with prenatal stress or MIA exposure
0.70
Safety concerns
0.00
Off-target
0.00
Trial stage
Preclinical (animal model)
0.90
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
Improved spatial learning and memory, improved hippocampal synaptic plasticity (LTP), increased PSD-95 expression
0.85
Approved
Yes (for other indications)
0.90